Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|p53-SLP vaccine||p53 Vaccine 5||A vaccine consisting of synthetic peptides derived from the middle part of p53 used to stimulate the host immune system to mount a cytotoxic T-cell lymphocyte response against p53-expressing tumor cells (PMID: 26334096).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 wild-type||ovarian cancer||no benefit||p53-SLP vaccine||Phase II||Actionable||In a Phase II trial, p53-SLP vaccine was demonstrated to be safe, well tolerated and to induce p53-specific T-cell responses in ovarian cancer patients; however clinical impact was lacking (PMID: 19621448, PMID: 21328579).||21328579 19621448|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|